ORIX Corporation (IX) valuation

Bring your own price

Enter a share price and a discount rate — every multiple, the earning-power value and the reverse-DCF below recompute on the spot from ORIX Corporation's latest SEC EDGAR filings. Change either input and the whole page follows.

ORIX Corporation reports in JPY, so every figure on this page is in JPY as filed — enter a share price in JPY (its home-market price, not a USD ADR quote) so the multiples line up. Ratios (P/E, EV/EBITDA, the EPV and reverse-DCF margins) are currency-neutral.
¥
%
Enter a share price to run the model.

The prefilled 8.9% is a plain CAPM cost of equity at β = 1: the 10-year Treasury yield (4.46%, 2026-06-18, U.S. Treasury 10-yr) plus the U.S. equity risk premium (4.46%, Damodaran 2026-01-01). Build a firmer per-company rate with the cost-of-equity and WACC calculators, then paste it here.

Share price · awaiting your input

Market Capitalization

Equity value at your price

Price-to-Earnings

P/E · Trailing Diluted

Earnings Yield

EPS ÷ Price · Trailing

Price-to-Free-Cash-Flow

P/FCF · Trailing

Free-Cash-Flow Yield

FCF Yield · Trailing

Price-to-Sales

P/S · Trailing

Price-to-Book

P/B · Latest filing

Fundamentals from the filings

Every model input below comes straight from ORIX Corporation's SEC EDGAR XBRL filings — these are the denominators and bridge inputs the calculator pairs with your price and rate.

Trailing twelve months · TTM as of 2025-09-30 (Q2 FY2026)

Revenue
¥1.39T
EBIT (GAAP)
¥377.73B
EBIT margin
27.1%
Operating cash flow
¥1.31T
CapEx
D&A
¥399.22B
Free cash flow
YoY revenue growth

Balance sheet · 6-K · period ending 2025-09-30

Cash & equivalents
¥1.28T
Total debt
¥6.52T
Stockholders' equity
¥4.44T
Excess cash
¥1.28T

Total debt = Long-term debt (¥5.91T) + Short-term borrowings (¥609.88B) .

Share count

Diluted shares (TSM-scaled)
1165.6M

Method: point-in-time shares outstanding × 1.0023 (latest filer-disclosed diluted ÷ basic ratio). See the diluted-shares methodology for why this count denominates EPV/share and the reverse-DCF equity bridge.

Earning-Power-Value, reverse-DCF, and EV/EBITDA are hidden for this insurer. EPV and the reverse-DCF both anchor on an EBIT margin, but a insurer's "margin" is interest-spread × leverage with non-EBIT investment results mixed in; EV/EBITDA omits deposits and borrowings — the actual funding — so the multiple isn't interpretable. The trailing multiples above (P/E, P/S, P/B, P/FCF) still render, but the right lens here is price-to-tangible-book-value and ROE vs cost of equity — applied manually, outside this page.

What these ratios mean & how they're built: see the valuation ratios glossary on the Financials methodology page — per-ratio definitions and the exact us-gaap concepts behind each numerator and denominator.

Sources. Fundamentals come from SEC EDGAR XBRL filings for IX (CIK 0001070304). The share price and the discount rate are inputs you supply — nothing on this page is a market quote, and the page fetches no market data. Per-share denominators are split-adjusted to today's share count.

Related tickers

HBUV

Hubilu Venture Corporation

RBKB

Rhinebeck Bancorp, Inc.

ARCT

ARCTURUS THERAPEUTICS HOLDINGS INC.